cyrilzakka/clinical-trials huggingface dataset:
Nerve Injury in the Hand, an Interview Study

This qualitative study sought to explore the exerience of change in physical activity due to nerve injury in the arm and hand.

Aim:

Has the physical activity level changed in connection with the nerve injury. Experiences of factors influensing this change.

Population: Patients surgically treated for digital,median,ulnar-or plexus nerveinjuries at Södersjukhuset or Universitets sjukhuset in Linköping. 1-3 years ago. Age 18-75.

Method: Interviews are carried out over the phone, digitally recorded and trascribed. The analysis is inductive approach.

Eligibility Criteria:
Inclusion Criteria:

* Injury to the median, ulnar or digital nerve or injury to the brachial plexus.
* 1-5 years post injury.

Exclusion Criteria:

* Severe psychiatric disease.
* Drug or alcohol abuse.
* Insufficient language understanding.
* Severe diabetes mellitus with nerve complications.
Alternate Day Buprenorphine Administration, Phase X - 15

The purpose of this study is to determine how subjects will make changes in the amount of medication received when given a monetary alternative to buprenorphine.


Eligibility Criteria:
Please contact site for information.
The Efficacy of Interferential Current Treatment on Knee Osteoarthritis

The effects of different carrier frequencies of interferential current on pain and function in patients with knee arthrosis will be compared

60 patients with knee osteoarhthritis will be enrolled in the study. Subjects will be randomized to 3 groups. All patients will receive interferential currents to both their knees, with different carrier frequencies (2, 4 and 8 kilohertz (kHz) respectively). The effect of different types of carrier frequencies on pain, 10 meter walk test will be analysed.

Eligibility Criteria:
Inclusion Criteria:

* Age between 50-80 years
* Knee VAS pain scores ≥ 4
* Kellgren-Lawrence radiologic scores 2 and 3

Exclusion Criteria:

* History of knee surgery
* Inflammatory arthritis
* Paralysis of lower extremities
* Serious cardiovascular disease /presence of cardiac pacemaker
* Severe osteoarhthritis of lower extremity joints other than the knees
* History of newly diagnosed cancer (ın the last 6 months)
* Cognitive impairment
Medtronic Reveal XT Study

While surgical treatment for atrial fibrillation (AF) has been performed for over 20 years, virtually all of the historical series reported only the recurrence of symptomatic AF and have used only intermittent electrocardiogram (ECG) follow-up. This study compares the use of traditional arrhythmia assessment (ECG and 24-hour holter monitoring) with the use of the Medtronic Reveal XT device to continuously record heart rhythm to quantify postoperative arrhythmia burden following surgical treatment for AF in patients undergoing either lone or concomitant heart surgery.


Eligibility Criteria:
Inclusion Criteria:

1. Patients undergoing planned, elective AF surgery, either as a stand-alone procedure or as a concomitant cardiac operation.
2. Patients will have either a Cox-Maze procedure (full-biatrial lesion set) or surgical pulmonary vein isolation (PVI).
3. Patients 18 years or older.
4. All eligible patients will be considered, regardless of gender or race.
5. Patients able and willing to provide informed consent and willing to comply with the required interval follow-up.

Exclusion Criteria:

1. Patients with a preoperative permanent pacemaker.
2. Patients with a projected lifespan of less than six months.
3. Patients requiring emergent cardiac surgery.
4. Patients unwilling or unable to give written informed consent.
5. Patients undergoing a right atrial or left atrial lesion set procedure.
PApillomavirus in REnal Transplant Patient

The main goal of project is to study the distribution of HPV genotypes in the anogenital area and peripheral humoral immune responses HPV (total and neutralizing Ab) before and after renal transplantation. Furthermore, the investigators wish (i) establish whether there is a correlation between HPV infection and HPV immune response before and after transplantation, and (ii) determine whether there is a link between HPV infection and immunosuppression.

Kidney transplant patients, iatrogenic immunosuppression established, essential to limit the transplant. Kidney transplant patients, iatrogenic immunosuppression established, essential to limit the transplant rejection, exposes patients to an increased risk of infections, including human papillomavirus (HPV).

These patients thus constitute a population at risk of developing cancers associated with HPV. Indeed, a recent meta-analysis indicated that the standardized incidence ratio for cancers associated with HPV increases dramatically in kidney transplant: SIR of 2.13 (95% CI 1.37 to 3.30) for the cervical, RIS 22.76 (95% CI 15.8 to 32.7) for the vulva and vagina, RIS 15.8 (95% CI 5.79 to 34.40) for the penis, RIS 4.85 (95% CI 1.36 to 17.3) and RIS to the anus of 3.23 (95% CI 2.40 to 4.35) for the oral cavity and pharynx. In fact, transplant patients are subject to increased surveillance to detect the onset and / or progression of lesions (pre) cancerous, especially anogenital level. Data on HPV infection in the genital area of kidney transplant patients are few and concern cohorts with a modest number of subjects. Indeed, it is difficult to estimate the prevalence of infection and know precisely genotypes of HPV present in anogenital level. Similarly, some studies report the presence of anti-HPV antibodies in transplant patients.

The main goal of project is to study the distribution of HPV genotypes in the anogenital area and peripheral humoral immune responses HPV (total and neutralizing Ab) before and after renal transplantation. Furthermore, the investigators wish (i) establish whether there is a correlation between HPV infection and HPV immune response before and after transplantation, and (ii) determine whether there is a link between HPV infection and immunosuppression.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged over 18 years
* Patient waiting for first kidney transplant
* Patients receiving a social security scheme
* Postmenopausal women, surgically sterile or subjected to an effective method of contraception
* Patient who signed the written consent

Exclusion Criteria:

* Patients who have been transplanted
* Pregnant women
* Emergency situation Patients
* Patients unable to give consent personally
* Major protected Patients
* Patients under judicial supervision
Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells

For most patients with hepatocellular carcinoma, surgery or other curative procedures are not possible and only palliative measures could be applied (chemoembolization, targeted drugs, best supportive cares, etc). In the ICAR study, increasing doses of a cell therapy product will be evaluated in patients in a palliative setting. All patients will have one hepatic intra-arterial injection of immunological cells (gamma-delta T lymphocytes) and will be evaluated for safety.


Eligibility Criteria:
Inclusion Criteria:

* Adult over 18
* Hepatocellular carcinoma histologically proven, with at least one measurable tumor
* Non operable tumor
* Alfa foeto protein \> 400 ng/ml
* Other treatments (surgery, chemoembolization) non indicated
* Chemoembolization non indicated due to good performance status (WHO 1) or to tumor volume
* Performance status WHO \< 2
* Life expectancy \> 3 months

Non inclusion Criteria:

* Extra hepatic metastases
* Severe hepatopathy (Child B or C)
* Virus B or C chronic hepatitis
* Chronic cardiac failure
* Uncontrolled severe infectious disease
* Other cancer, if not considered as cured
* Positive serology for HIV or HTLV
* Leucocytes \< 3000/mm3 or neutrophils \< 1500/mm3
* Platelets \< 80000/mm3
* Serum creatinine \> 110 µmol/L
* Bilirubin \> 35 µmol/L
* AST, ALT, alkaline phosphatase \> 5N
* Current immunosuppressive treatment
* Impossibility to comply with scheduled follow-up
* Anatomical situation not permitting the selective injection of the product of cell therapy
* Pregnant or breastfeeding woman, or not using adequate effective contraceptive method

Exclusion Criterion:

* Insufficient number of gamma delta lymphocytes after expansion
Noninvasive Cardiac Imaging in Vasospastic Angina Korean Registry (NAVIGATOR)

With regard to the characteristics of spasm segment, had been clearly described by other invasive imaging methods including intravascular ultrasound and optical coherence tomography. However, there is potential risk during these invasive procedures, such as severe myocardial ischemia or fatal arrhythmia.

Presently available imaging test for coronary artery disease in multi detector-row computed tomography angiography (MDCTA) evaluation has high diagnostic accuracy to evaluate coronary artery stenosis. However, previous report assessing imaging findings or diagnostic accuracy of MDCTA in patients with vasospastic angina (VSA) is lacking.

Previously investigators analyzed the characteristics of coronary spasm segment in an observational individual dataset, suspected VSA patients (n=20) underwent dual-acquisition of MDCTA (initial and intravenous nitrate injected CT imaging), the diagnostic accuracy showed sensitivity: 73%, specificity: 100%, positive predictive value: 100%, and negative predictive value: 56%.

Further study is necessary because previous analysis presented limited sample size and deficiency of healthy control.

Therefore, investigators hypothesis that dual-acquisition of MDCTA in noninvasive tool for coronary assessment provide more information of coronary characteristics, and the diagnostic efficacy would be non-inferior as compared with the invasive coronary imaging modality in coronary spasm-induced angina attacks.

Eligibility Criteria:
Inclusion Criteria:

* Subject is onset of angina-like attack at rest, during effort, or during rest and effort.
* Subject has chest pain between night and early morning.
* Subject is scheduled to undergo MDCTA.
* Subject is an acceptable candidate for CAG with an EG provocation test.
* Cardiac condition: BP\>90/60mmHg, ECG: sinus rhythm with regular, left ventricular ejection fraction\>55%, and resting heart rate\<100 beats/min.
* Subject will be provided written informed consent.
* Subject is willing to comply with study follow-up requirement.

Exclusion Criteria:

* Subject has clinical evidence of acute coronary syndrome.
* Subject has evidence of significant narrowing (\>50% stenosis by CAG).
* Subject has clinical evidence of cardiomyopathy or valvular heart disease.
* Subject is hemodynamically unstable.
* Subject has a history of PCI and CABG.
* Subject is pregnant and/or breastfeeding or intends to become pregnant during the duration of the study.
* Subject has known allergy to contrast medium.
* Subject has renal insufficiency (serum creatine \>2.5 mg/dl).
Microneedling for Burn Hypertrophic Scars

Approximately 33 to 91% of severe burn victims will develop hypertrophic scars. Hypertrophic scars are defined as erythematous (red), raised and rigid scars that can cause pain and itching, among other things. They cause psychological distress and affect the quality of life of burn victims. Microneedling is a technique that uses an electrical device to create hundreds of microchannels that penetrate the skin layers. This study is interested in determining the effectiveness of microneedling in improving the pliability, thickness and erythema of hypertrophic scars. Each scar will receive up to 5 ACS-pen treatments followed by the application of cortisone (triamcinolone acetonide). Knowing that microneedling increases the absorption of products applied to the skin by about 80%, it is logical to think that creating these channels to the dermis and applying cortisone afterwards would have a beneficial effect on the hypertrophic scars of these patients.

Patients will receive microneedling once every six weeks for a maximum of five treatments

Eligibility Criteria:
Inclusion Criteria:

* Any gender or race
* 16 years of age or older
* Have at least 2 HSc that meet the clinical criteria for HSc
* Provide written informed consent.

Exclusion Criteria:

* Patients with keloid scars
* Mature scar site
* A psychiatric condition or cognitive impairment that interferes with their ability to follow the treatment protocol
* Dermatological conditions (i.e. psoriasis, eczema, etc.) in the area of the evaluation site
* An allergy to ultrasound gel
* On anticoagulant medications
* Inability to understand English or French.
MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b

This is a placebo-controlled clinical trial to assess the efficacy and safety of a combination of lopinavir/ritonavir and Interferon beta-1b in hospitalized patients with MERS.

The aim of this study is to investigate the efficacy and safety of lopinavir /ritonavir and recombinant Interferon beta-1b combination given with optimal supportive care compared to placebo with optimal supportive care for patients with laboratory-confirmed MERS-CoV infection requiring hospital admission.

Eligibility Criteria:
Inclusion criteria at eligibility assessment

1. Adult (defined as ≥18 years of age);
2. Laboratory confirmation of MERS-CoV infection by reverse-transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source; and
3. New organ dysfunction that is judged to related to MERS including: hypoxia defined as requirement of supplemental oxygen to maintain oxygen saturations \>90%, hypotension (systolic blood pressure\<90 mmHg) or need for vasopressor/inotropic medication, renal impairment (increase of creatinine by 50% from baseline, glomerular filtration rate reduction by \>25% from baseline or urine output of \<0.5 ml/kg for 6 hours - Risk stage by RIFLE criteria), neurologic (reduction of Glasgow Coma Scale by 2 or more, i.e. 13 or lower of 15 points), thrombocytopenia (\<150,000 platelets/mm3) or gastrointestinal symptoms that requires hospitalization (e.g. severe nausea, vomiting, diarrhea or/and abdominal pain).

Exclusion criteria at eligibility assessment

1. Suicidal ideation based on history (contraindication to interferon (IFN)-β1b);
2. Known allergy or hypersensitivity reaction to lopinavir/ritonavir or to recombinant IFN-β1b, including, but not limited to, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, urticaria or angioedema;
3. Elevated alanine aminotransferase (ALT) \>5 fold the upper limit in the hospital's laboratory;
4. Use of medications that are contraindicated with lopinavir/ritonavir and that cannot be replaced or stopped during the study period, such as CYP3A inhibitors;
5. Pregnancy - eligible and consenting female participants in childbearing age will be tested for pregnancy before enrollment in the study;
6. Known HIV infection, because of concerns about the development of resistance to lopinavir/ritonavir if used without combination with other anti-HIV drugs; or
7. Patient likely to be transferred to a non-participating hospital within 72 hours.
Neurological Changes With a Memory Self-efficacy Training Protocol

Confidence in one's ability to accomplish a task, more formally known as self-efficacy, is an important psychological variable that can influence how the investigators perform on various tasks. Previous studies have shown that self-efficacy is a modifiable trait that can be improved and bolstered with training and practice. More importantly for this study, memory self-efficacy has been shown to be modifiable for older adults, consequently improving their performance on memory tasks. While there is evidence to support the importance of memory self-efficacy for successful memory performance in older adults, the underlying neurological changes that accompany these performance changes have not been explored. The goal of this study is to examine the changes in brain activity before and after a memory self-efficacy training program to better understand the mechanisms of both memory and self-efficacy.


Eligibility Criteria:
Inclusion Criteria:

1. Subjective memory complaints within past 5 years
2. Objective memory impairment below age norms on standardized cognitive testing
3. Score below 25 on Montreal Cognitive Assessment
4. Scores 1.5 standard deviations below age norms on memory testing
5. Unimpaired performance in Activities of Daily Living
6. Intact general cognition
7. Fluently read, write and speak English
8. Right handed

Exclusion Criteria:

1. Co-morbidity that would impact cognition (depression, anxiety, stroke)
2. Prior diagnosis of dementia of any type
3. Use of prescription or recreational drug use that would impact cognition (excluding hormone replacement therapy)
4. Uncorrected visual or auditory deficits/impairments
5. Current participation in alternate study
Health and Employment After Gastro Intestinal Surgery - HEAGIS2

By using the M.A.D.I.T. methodology and the Dialogics science, SALVO Project aims to develop operational guidelines to support oncological target patients in the resumption of their daily post-operative activities. The research will implement an instrument for the purpose of measuring the health need of participants who are admitted to the surgical ward. Therefore, targeted interventions will be implemented with participants, and efficacy will be evaluated in order to define treatment guidelines.

The principal aim of this study is to create a validated and replicable intervention model for supporting patients who undergone surgery for esophageal and gastro intestinal cancer.

Several studies highlight how patients diagnosed with a digestive tract cancer, experience difficulties in returning to work after treatment, leading to socio-economic spill-over effects.

A specific 16 questions questionnaire had been developed for this study, the "Health and Employment After Gastro Intestinal Surgery Dialogical Questionnaire" (HEADS-DQ). It investigate peculiar patient competences involved after surgery: future forethought; context evaluation; consequences of own actions forethought; use of available resources, each relevant to four areas: clinical; familiar; working; daily-activities.

Through this questionnaire participants ability in dealing with after surgery consequences will be evaluated in order to describe their development during the post surgery period.

Eligibility Criteria:
Inclusion Criteria:

* \>18 years old;
* Comprehension of Italian language;
* Esophageal or gastrointestinal cancer diagnosis;
* Curative surgery;
* No metastasis or neoplasm recurrence.

Exclusion Criteria:

* \<18 years old;
* No comprehension of Italian language;
* Not esophageal or gastrointestinal cancer diagnosis;
* Palliative surgery;
* Metastasis or neoplasm recurrence.
Clearpath Miniprep Colonoscopy Study

Use of Clearpath to facilitate successful completion of colonoscopy procedures with sub-optimal preparation.


Eligibility Criteria:
Inclusion Criteria:

1. Patient 18-70 years
2. Scheduled for colonoscopy
3. Providing informed consent

Exclusion Criteria:

1. Known large polyps (\> 2 cm) for polypectomy
2. Inflammatory Bowel Disease (IBD)
3. Previous colonic surgery
4. Known or suspected stricture
5. Significant co morbidity
6. Significant diverticular disease
7. Contraindicated to receive oral Sodium Picosulfate solution
Splint Versus Steroid Randomized Trial

The primary aim is to compare the effectiveness of splinting versus steroid injection in improving the DASH scores in participants diagnosed with De Quervain's tenosynovitis over a period of 6 months.

The primary hypothesis is that steroid injection into the first dorsal compartment is more effective compared with splinting at 3 months.

The secondary hypothesis is that steroid injection yields better clinical outcomes compared with splinting at 1 month, 3 months and 6 months.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis of de Quervain's tenosynovitis based on the de Quervain's screening tool (DQST) with scores ≥ 5 (refer to table 1)
* No prior treatment
* Above 21 years of age

Exclusion Criteria:

* Allergy to steroid (triamcinolone acetate) or local anaesthetic (lignocaine)
* History of work related trauma
Predictive Models for Betalactam Allergy

Background: ß-lactam (BL) antibiotics represent the main cause of allergic reactions to drugs, inducing both immediate and non-immediate reactions. The diagnosis is well established, usually based upon skin tests and drug provocation tests, but cumbersome.

Objectives: To design predictive models for the diagnosis of BL allergy, based on the clinical history of patients with suspicions of allergic reactions to BL.

Methods: The study included a retrospective phase in which records of patients consulting and explored for a suspicion of BL allergy (in the Allergy Unit of the University Hospital of Montpellier between September 1996 and September 2012) where used to construct predictive models; a prospective phase, in which we performed an external validation of the chosen models, in patients with suspicion of BL allergy recruited from 3 allergy centres (Montpellier, Nîmes, Narbonne), between March and November 2013. Data related to clinical history and allergy work-up results were retrieved and analysed. Logistic regression and decision tree method were used to design two models to predict the diagnosis of allergy to BL.


Eligibility Criteria:
Inclusion Criteria:

* Patients seen in consultation in allergology department for suspicion of allergy to beta lactamines

Exclusion Criteria:

* patient refusal to take part in the study
* pregnancy
* breast feeding women
* contraindication to provocation test
Effect of Probiotics on Regulating Gut Health and Blood Lipid in Adults

The purpose of this study was to evaluate the efficacy of 1 capsules (300 mg per capsule) of Nutrarex Probiotic Capsules per day in regulating gut health and blood lipid in adults by clinical trial.

This experiment is carried out in a controlled manner. Before the subjects enter the research experiment, they need to follow their original lifestyle. The habits of maintaining a constant body weight for more than 2 weeks before the test, such as calorie balance in the diet and the amount of activity. Then enter the test to carry out the evaluation test of probiotics to the end. 50 subjects were randomized, 25 to placebo and 25 to probiotics. The subjects took one capsules of Nutrarex probiotics daily, a total of 300 mg. Continue to take it for 4 weeks, and perform blood routine tests. Body composition detection, waist and hip circumference measurement, related index analysis and 24-hour dietary questionnaires, gut health questionnaires and stool samples were collected and analyzed for 4 weeks before and after treatment.

Eligibility Criteria:
Inclusion Criteria:

* male or female participants
* aged 20-65 years old
* body mass index in 25-27 kg/m2 or body fat \> 25% for men and \> 30% for women

Exclusion Criteria:

* cancer, chronic heart disease, use drugs which pharmacological effects may affect immunity having systemic infections
* using probiotics.